Business Wire

Remarkable Success of Mobile and Contactless Payments Through Near Field Communication “NFC” Technology Boosting the Aim of a Less Dependent on Cash Society Within the Kingdom of Saudi Arabia

10.11.2020 15:51:00 EET | Business Wire | Press release

Share

As Saudi Arabia’s national payments infrastructure operator, Saudi Payments has the task of driving the Kingdom’s digital transformation towards a less dependent on cash society. Its aim, under the Kingdom’s Vision 2030 roadmap, is to ensure 70% of all transactions in the country are digital by 2030, and its secret weapon towards achieving this, is through digital and mobile payments (utilizing Near Field Communication “NFC” technology within physical cards and mobile devices).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005684/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

NFC and Mobile Payments in Saudi Arabia (Photo: AETOSWire)

Introduced only four years ago, mobile and NFC payments have rapidly become the payment of choice for a largely young, youth and tech savvy Saudi and non-Saudi citizens within the society. The rate of growth has been phenomenal, increasing from 97 million transactions in September 2019, to over 266 million contactless transactions with a value of SAR 27.5 billion. That represents 174% increase comparing to same period in 2019.

The Saudi population is young, in a nation of 35 million people, two thirds are under the age of 35. The Kingdom is also one of the highest users of mobile phones in the world, with over 28 million registered smartphones. The Millennials and Gen Z have grown up in a digital age where they expect to have technology to their fingertips to make payments. “Cash is fast” terminology is becoming a phase of the past.

There are currently over 22 million NFC mada cards in circulation in the Kingdom. In the third quarter of 2020, mobile payments represented 24% of all POS payments, an increase of 567% compared with 2019.

Saudi Payments Managing Director Fahad Al-Akeel said: “The growth in digital and mobile payments has outstripped expectation, Saudi Payments strategy is to enrich the Kingdom’s digital and mobile payment environment and make it more competitive. Our aim is to support the National Digital Transformation under Vision 2030 by enabling the Kingdom of Saudi Arabia to become essentially a less dependent on cash society during the next ten years, if not even achieved beforehand.

However, the speed with which the technology has been adopted has surpassed all expectation. In September 2020 91% of transactions were contactless, compared with 66% in 2019. There are also now over 614K POS terminals across the country, 96% of which are NFC enabled.”

Fahad Al-Akeel acknowledges and emphasizes that COVID-19 has had a positive impact on speeding up the transition, “The huge growth this year in digital and mobile payments could be attributed to COVID-19 and cardholders increasingly turning to online shopping and preferring to use cards and mobile at point of sales “POS” instead of cash. The result has meant we have exceeded all forecasts, with 25% mobile Payments Volume share vs overall POS Volume as of September 2020, compared to 8% in September 2019, an overall increase of 495%.

Saudi Payments developed its universal mobile payments infrastructure in 2018, in connection with all card issuers in the Kingdom, which rapidly lead to the introduction of NFC based payment solutions such as mada Pay and Apple Pay. The overwhelming success of the infrastructure means further OEM and international Pays are anticipated to come on line in the near future.

More recent developments have included an NFC limit/CDCVM/CVM/ PIN free which is applicable on physical NFC mada cards. The single transaction limit on physical cards and mada pay was increased in March 2020 from SAR 100 to SAR 300, in order to minimize the chance of COVID-19 infection and increase the share of contactless payments by simply tapping the card or mobile device without the need of a PIN entry at the POS terminal.

These multiple steps have collectively made NFC a cultural phenomenon which could easily see the Kingdom achieve its Vision 2030 goal of creating a cashless society well before 2030.

Saudi Payments is a fully owned subsidiary of the Saudi Arabian Monetary Authority (SAMA)

About Saudi Payments

Saudi Payments was established in 1991 to operate and develop all major national payment systems.

Since its establishment, it has played a vital role in enabling the public and private sectors to connect with domestic and international payment services, helping to develop the Kingdom’s payment infrastructure.

Saudi Payments provides fast, flexible, and safe electronic payment services at low cost, through mada, SADAD and Esal systems, enhancing the national electronic payment infrastructure and reducing cash transactions.

Saudi Payments supports the government’s Financial Sector Development Program, a part of the Kingdom's Vision 2030 Program. Saudi Payments operates to international standards, connecting local and international service providers with payment networks, reducing the need for cash payments.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Showmer Alshowmer
External Communication Manager
SAUDI PAYMENTS
E Saalshowmer@saudipayments.com
T +966-11-8292000-2045

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye